MSNs |
Dexamethasone |
BMSCs |
Bone targeting |
Bone tissue regeneration |
616
|
Mice |
Osteoporosis |
MSNs |
BMP-2 |
MSCs |
None |
Bone tissue regeneration |
617
|
pDNA |
MSNs |
BFP-BMP-7 |
MG-63 |
None |
Bone tissue engineering |
618
|
hMSCs |
MSNs |
BMP-2 |
BMSCs |
Ectopic bone formation |
Bone tissue engineering |
619
|
Dexamethasone |
Rats |
MSNs |
QK peptide |
HUVEC |
Critical-sized calvarial defect |
Bone tissue engineering |
620
|
Dexamethasone |
BMSCs |
Rats |
MSNs |
Enoxacin |
S. aureus
|
Infection model |
Bone tissue engineering and infection |
621
|
BMMs |
Rats |
MSNs |
miR-26a |
BMSCs |
None |
Bone tissue regeneration |
622
|
MSNs |
(rno)-miRNA-26a-5p |
BMSCs |
None |
Bone tissue engineering |
623
|
MSNs |
Cu2+
|
Macrophages |
None |
Bone tissue engineering |
624
|
BMSCs |
MSN-G3 |
Levofloxacin |
MC3T3-E1 |
None |
Bone tissue engineering and infection |
625
|
Zn2+
|
E. coli
|
MSNs |
Ag+
|
BMSCs |
None |
Bone tissue engineering and infection |
626
|
PDGF-BB |
E. coli
|
S. aureus
|
P. aeruginosa
|
C. sporogenes
|
B. fragilis
|
MSNs |
Lactoferrin |
ADSCs |
None |
Bone tissue regeneration |
627
|
Osteoporosis |
Ce@MSNs |
|
MC3T3-E1 |
None |
Osteoporosis |
627
|
RAW264.7 |
MSNs |
Licorice-ISL |
BMMs |
Calvarial bone erosion |
Osteoporosis |
628
|
Mice |
MSNs |
17β-E2 |
MC3T3-E1 |
OVX |
Osteoporosis |
629
|
Mice |
MSNs (TDNs) |
MCP-1 |
BMMSCs |
OVX |
Osteoporosis |
630
|
Mice |
MSNs |
SOST SiRNA |
MEFs |
OVX |
Osteoporosis |
615 and 631
|
Osteostatin |
Mice |
MSNs |
DOX |
MG-63 |
None |
Osteosarcoma |
632
|
Fe-MSNs magnetic responsive |
PLK1 siRNA |
KHOS |
None |
Osteosarcoma |
633
|
MNC-MSNs pH-responsive |
PLK1 SiRNA |
KHOS |
None |
Osteosarcoma |
634
|
MSNs ultrasound responsive |
DOX |
HOS |
None |
Osteosarcoma |
635
|
MSNs pH-responsive |
DOX |
HOS |
None |
Osteosarcoma |
291
|
MSNs pH Responsive |
BMP-2 |
BMSCs |
Ectopic bone formation |
Bone tissue regeneration |
636
|
Dexamethasone |
Mice |
MSN enzyme responsive |
Ag+
|
S. aureus
|
Femur defect |
Bone tissue regeneration and infection |
637
|
Rats |
MSN-PEM/Ti |
17β-E2 |
OBs |
None |
Bone tissue engineering |
638
|
MSN/nanofibrous scaffold |
BMP-2 |
C2C12 |
None |
Bone tissue engineering |
639
|
Deferoxamine |
hMSCs |
MSN/GelMA hydrogel |
Metformin |
SHEDs |
None |
Bone tissue regeneration |
640
|
MSN/HA |
Zoledronic acid |
L-929 |
None |
Bone tissue regeneration |
641
|
BMMs |
MSN/PLLA/PCL scaffolds |
Dexamethasone |
BMSCs |
Calvarial bone defect |
Bone tissue regeneration |
642
|
Rats |
nHA/MSNs |
Dexamethasone |
MC3T3-E1 |
Calvarial bone defect |
Bone tissue engineering |
643
|
Rats |
MSN/PLGA-PNIPAM hydrogel |
miRNA-222 |
BMSCs |
Mandibular defect |
Bone tissue engineering |
644
|
Aspirin |
Rats |
MSN/PCL nanofiber scaffold |
COL1A1 SiRNA |
HDFs |
Subcutaneous implantation |
Bone tissue regeneration |
645
|
Rats |